Noopur Raje, MD, on Unmet Needs With CAR T-Cell Therapy in Multiple Myeloma

Video

The director of the Center for Multiple Myeloma and Mass Gen discussed unmet needs with CAR T-cell therapy in multiple myeloma.

This content originally appeared on our sister site, OncLive.

Access remains the most prevalent unmet need regarding CAR T-cell therapy, which is currently approved only for patients with late-stage relapsed or refractory multiple myeloma. Patients must wait and sometimes cannot receive the products in time.

OncLive spoke with Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusets General Hospital, about these unmet needs with CAR T-cell therapy in multiple myeloma. She discussed how improving access for these patients is a vital concern.

Raje discussed the potential of moving CAR T-cell therapy into earlier stages of treatment to help improve access and expand the number of patients who could receive treatment. Ciltacabtagene autoleucel (cilta-cel; Carvykti) and idecabtagene vicleucel (ide-cel; Abecma) are currently being investigated in the up-front setting in clinical trials. Once the indication is received in earlier stages of myeloma, bridging therapies will help more patients receive CAR T-cell therapy, Raje concluded.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
Damien Maura, PhD, a senior scientist at Voyager Therapeutics
© 2025 MJH Life Sciences

All rights reserved.